Ratings by Baird (Madhu Kumar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/5/2024 | Cellectis | CLLS | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/30/2023 | Eiger BioPharma | EIGR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2022 | Eiger BioPharma | EIGR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/19/2022 | AVEO Pharmaceuticals | AVEO | Downgrade | Neutral (Outperform) |
10.48 (15.00) |
43.13% | Details | |
| 5/18/2022 | Cellectis | CLLS | Upgrade | Outperform (Neutral) |
3.48 (3.56) |
2.3% | Details | |
| 10/8/2021 | Cellectis | CLLS | Downgrade | Neutral (Outperform) |
12.02 (3.56) |
-70.38% | Details | |
| 3/16/2021 | Cellectis | CLLS | Upgrade | Outperform (Neutral) |
21.76 (3.56) |
-83.64% | Details | |
| 1/20/2021 | Gritstone Oncology | GRTS | Downgrade | Underperform (Outperform) |
22.27 (0.03) |
-99.87% | Details | |
| 12/29/2020 | Arcturus Therapeutics | ARCT | Downgrade | Neutral (Outperform) |
98.13 (7.11) |
-92.75% | Details | |
| 12/28/2020 | Aprea | APRE | Downgrade | Neutral (Outperform) |
25.09 (0.90) |
-96.41% | Details | |
| 12/22/2020 | Intellia Therapeutics | NTLA | Downgrade | Neutral (Outperform) |
55.41 (13.44) |
-75.74% | Details | |
| 12/21/2020 | Arrowhead Pharma | ARWR | Downgrade | Neutral (Outperform) |
79.37 (59.82) |
-24.63% | Details | |
| 11/24/2020 | Eiger BioPharma | EIGR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2020 | Editas Medicine | EDIT | New Coverage | Underperform (N/A) |
30.94 (2.00) |
-93.54% | Details | |
| 9/1/2020 | Cue Biopharma | CUE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2020 | Homology Medicines | FIXX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2020 | Cellular Biomedicine Group | CBMG | Downgrade | Neutral (Outperform) |
14.27 (19.75) |
38.4% | Details | |
| 8/12/2020 | Vir Biotechnology | VIR | Maintain | Underperform (N/A) |
|
Details | ||
| 8/12/2020 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2020 | uniQure BV | QURE | Upgrade | Outperform (Neutral) |
37.71 (14.27) |
-62.16% | Details | |
| 7/24/2020 | Arbutus Biopharma | ABUS | Downgrade | Neutral (Outperform) |
2.82 (4.53) |
60.64% | Details | |
| 7/13/2020 | Cellular Biomedicine Group | CBMG | Upgrade | Outperform (Neutral) |
14.90 (19.75) |
32.55% | Details | |
| 7/7/2020 | Cellectis | CLLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2020 | uniQure BV | QURE | Downgrade | Neutral (Outperform) |
67.74 (14.27) |
-78.93% | Details | |
| 6/1/2020 | Cellectis | CLLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | AVEO Pharmaceuticals | AVEO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/29/2020 | AVEO Pharmaceuticals | AVEO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2020 | Cellectis | CLLS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2020 | Vir Biotechnology | VIR | Maintain | Underperform (N/A) |
|
Details | ||
| 5/12/2020 | Cellectis | CLLS | New Coverage | Outperform (N/A) |
15.08 (21.76) |
44.3% | Details | |
| 5/8/2020 | Dicerna Pharmaceuticals | DRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2020 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2020 | Aprea | APRE | New Coverage | Outperform (N/A) |
33.98 (25.09) |
-26.16% | Details | |
| 3/27/2020 | Vir Biotechnology | VIR | Maintain | Underperform (N/A) |
|
Details | ||
| 3/18/2020 | Cue Biopharma | CUE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Homology Medicines | FIXX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Pieris Pharmaceuticals | PIRS | Upgrade | Outperform (Neutral) |
2.23 (13.60) |
509.87% | Details | |
| 3/12/2020 | Arcturus Therapeutics | ARCT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2020 | Scholar Rock | SRRK | New Coverage | Outperform (N/A) |
15.71 (45.29) |
188.29% | Details | |
| 3/4/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2020 | Vir Biotechnology | VIR | Downgrade | (Underperform) |
0.00 (9.55) |
0% | Details | |
| 2/11/2020 | Leap Therapeutics | LPTX | New Coverage | Outperform (N/A) |
1.78 (2.06) |
15.73% | Details | |
| 2/11/2020 | Arcturus Therapeutics | ARCT | New Coverage | Outperform (N/A) |
12.03 (7.11) |
-40.9% | Details | |
| 1/16/2020 | Neon Therapeutics | NTGN | Downgrade | Neutral (Outperform) |
1.23 (3.07) |
149.59% | Details | |
| 12/12/2019 | miRagen Therapeutics | MGEN | Downgrade | Neutral (Outperform) |
0.64 (23.01) |
3495.31% | Details | |
| 12/6/2019 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2019 | Audentes Therapeutics | BOLD | Upgrade | Neutral (Underperform) |
29.03 (1.13) |
-96.11% | Details | |
| 11/25/2019 | The Medicines Company | MDCO | Downgrade | Neutral (Outperform) |
69.76 (84.90) |
21.7% | Details | |
| 11/25/2019 | Arrowhead Research | ARWR | Upgrade | Outperform (Neutral) |
49.06 (59.82) |
21.93% | Details | |
| 11/14/2019 | Vir Biotechnology | VIR | New Coverage | Neutral (N/A) |
13.15 (9.55) |
-27.38% | Details | |
| 11/12/2019 | Cellular Biomedicine Group | CBMG | Downgrade | Neutral (Outperform) |
17.67 (14.90) |
-15.68% | Details | |
| 11/5/2019 | Iovanace Biotherapeutics | IOVA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2019 | Dicerna Pharmaceuticals | DRNA | New Coverage | Outperform (N/A) |
16.27 (38.22) |
134.91% | Details | |
| 10/28/2019 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2019 | Arrowhead Research | ARWR | Downgrade | Neutral (Outperform) |
38.97 (59.82) |
53.5% | Details | |
| 10/10/2019 | Ra Pharma | RARX | Downgrade | Neutral (Outperform) |
22.69 (48.00) |
111.55% | Details | |
| 10/3/2019 | Audentes Therapeutics | BOLD | New Coverage | Underperform (N/A) |
26.35 (1.13) |
-95.71% | Details | |
| 10/3/2019 | Arrowhead Research | ARWR | New Coverage | Outperform (N/A) |
28.14 (38.97) |
38.49% | Details | |
| 9/12/2019 | Tocagen Inc. | TOCA | Downgrade | Neutral (Outperform) |
4.18 (1.26) |
-69.86% | Details | |
| 9/10/2019 | Rubius Therapeutics, Inc | RUBY | New Coverage | Underperform (N/A) |
9.41 (0.08) |
-99.15% | Details | |
| 9/10/2019 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
6.91 (33.19) |
380.32% | Details | |
| 9/10/2019 | Homology Medicines | FIXX | New Coverage | Outperform (N/A) |
20.21 (0.93) |
-95.4% | Details | |
| 7/30/2019 | Pieris Pharmaceuticals | PIRS | Downgrade | Neutral (Outperform) |
5.33 (13.60) |
155.16% | Details | |
| 7/26/2019 | Neon Therapeutics | NTGN | New Coverage | Outperform (N/A) |
3.51 (1.23) |
-64.96% | Details | |
| 7/26/2019 | Gritstone Oncology | GRTS | New Coverage | Outperform (N/A) |
9.81 (0.03) |
-99.69% | Details | |
| 7/26/2019 | Cue Biopharma | CUE | New Coverage | Outperform (N/A) |
6.94 (0.30) |
-95.68% | Details | |
| 7/25/2019 | The Medicines Company | MDCO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/21/2019 | Ra Pharma | RARX | New Coverage | Outperform (N/A) |
23.90 (22.69) |
-5.06% | Details | |
| 5/29/2019 | Anchiano Therapeutics | ANCN | New Coverage | Outperform (N/A) |
4.95 (4.71) |
-4.85% | Details | |
| 5/20/2019 | The Medicines Company | MDCO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2019 | Pieris Pharmaceuticals | PIRS | New Coverage | Outperform (N/A) |
3.31 (5.33) |
61.03% | Details | |
| 4/23/2019 | Rocket Pharmaceuticals | RCKT | New Coverage | Outperform (N/A) |
16.90 (4.41) |
-73.91% | Details | |
| 3/29/2019 | Apellis Pharmaceuticals | APLS | New Coverage | Outperform (N/A) |
19.05 (20.07) |
5.35% | Details | |
| 3/29/2019 | uniQure BV | QURE | New Coverage | Outperform (N/A) |
58.53 (14.27) |
-75.62% | Details | |
| 3/28/2019 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2019 | The Medicines Company | MDCO | New Coverage | Outperform (N/A) |
27.07 (84.90) |
213.63% | Details | |
| 3/8/2019 | Syndax Pharmaceuticals | SNDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2019 | Clementia Pharmaceuticals Inc. | CMTA | Downgrade | Neutral (Outperform) |
25.83 (26.35) |
2.01% | Details | |
| 2/7/2019 | Cellular Biomedicine Group | CBMG | New Coverage | Outperform (N/A) |
17.71 (19.75) |
11.52% | Details | |
| 2/7/2019 | Iovanace Biotherapeutics | IOVA | New Coverage | Outperform (N/A) |
9.50 (5.13) |
-46% | Details | |
| 2/4/2019 | AVEO Pharmaceuticals | AVEO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2019 | AVEO Pharmaceuticals | AVEO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2019 | Inflarx NV | IFRX | New Coverage | Outperform (N/A) |
36.11 (37.29) |
3.27% | Details | |
| 1/29/2019 | Eiger BioPharma | EIGR | New Coverage | Outperform (N/A) |
14.30 (1.73) |
-87.9% | Details | |
| 1/18/2019 | Allena Pharmaceuticals | ALNA | New Coverage | Outperform (N/A) |
8.97 (0.08) |
-99.11% | Details | |
| 1/18/2019 | Tocagen Inc. | TOCA | New Coverage | Outperform (N/A) |
8.50 (4.18) |
-50.82% | Details | |
| 1/18/2019 | Clementia Pharmaceuticals Inc. | CMTA | New Coverage | Outperform (N/A) |
13.89 (25.83) |
85.96% | Details | |
| 1/4/2019 | Syndax Pharmaceuticals | SNDX | New Coverage | Outperform (N/A) |
4.45 (22.07) |
395.96% | Details | |
| 1/4/2019 | miRagen Therapeutics | MGEN | New Coverage | Outperform (N/A) |
3.36 (23.01) |
584.82% | Details | |
| 1/4/2019 | AVEO Pharmaceuticals | AVEO | New Coverage | Outperform (N/A) |
1.83 (15.00) |
719.67% | Details |
